<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01887587</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00020384</org_study_id>
    <nct_id>NCT01887587</nct_id>
  </id_info>
  <brief_title>Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia</brief_title>
  <official_title>Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ehab L Atallah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study of vincristine, doxorubicin and dexamethasone (modified VXD) plus
      MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma,
      lymphoblastic lymphoma or mixed phenotype acute leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I study, escalating doses of MLN9708 will be combined with a fixed dose
      modified VXD regimen. The study drug, MLN9708, will be administered on day 1, 8, and 15. If
      the patient experiences a dose limiting toxicity (DLT) the dose of MLN9708 maybe reduced to
      the next dose level on day 8 or day 15 in that patient. DLT would be any grade 3 or more
      toxicity which is thought to be probably or definitely related to MLN9708. Three patients
      will be treated per dose level unless DLT is observed. The starting dose of MLN9708 will be
      2.3 mg orally on days 1, 8 and 15. If toxicity is seen at this level then dose may be reduced
      to 1.5 mg (dose level -1) . If no DLT is seen in the first 3 patients, the dose will be
      increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I
      design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with
      acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs
      would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six
      patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.
      The maximum tolerated dose (MTD) will be the highest dose administered at which no more than
      1 DLT was observed. All patients will be evaluated for hematopoetic stem cell
      transplantation. If patients achieve complete response (CR) and are eligible for
      hematopoietic stem cell transplantation (HSCT), they will proceed to HSCT. If they are not
      eligible, no donor is identified or if HSCT will be delayed, and the patient has achieved
      benefit, then treatment maybe repeated at the discretion of the investigator. A total of 9-18
      patients will be enrolled on the study. The study duration would be about 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    SAE- risk of overall protocol treatment outweighs benefits
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">February 29, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events.</measure>
    <time_frame>Baseline to 30 days post treatment; approximately 8 weeks</time_frame>
    <description>Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal Dose of MLN9708</measure>
    <time_frame>8 Weeks</time_frame>
    <description>This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Relapsed or Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsed or Refractory Lymphoblastic Lymphoma</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
Dexamethasone- 10 mg/m2 orally or IV on days 1-14
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.
For patients without central nervous system (CNS) involvement:
Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
Methotrexate 12 mg administered intrathecally on day 8
For patients with CNS involvement:
-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLN9708</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Ixazomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Doxil</other_name>
    <other_name>hydroxydaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>(modified VXLD) plus MLN9708</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>Dexasone</other_name>
    <other_name>Solurex</other_name>
    <other_name>Baycadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

        Inclusion

          -  Male or female patients 18 years or older

          -  Have relapsed B or T-precursor acute lymphocytic leukemia/lymphoma, lymphoblastic
             lymphoma or mixed phenotype acute leukemia with increased bone marrow or peripheral
             blood blasts by morphology with or without CNS involvement

          -  Prior therapy: At least two prior treatment attempts to induce remission with no limit
             on the number of prior treatment regimens.

          -  Patients are eligible after allogeneic stem cell transplantation

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Patients must meet the following clinical laboratory criteria:

               -  Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN).

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.

               -  Calculated creatinine clearance ≥ 30 mL/min

               -  Absolute neutrophil count (ANC) &gt; 1,000/cmm and platelets &gt; 75,000/cmm unless the
                  cytopenias are secondary to disease

          -  Life expectancy reasonably adequate for evaluating the treatment effect

          -  Patients must be at least 2 weeks from major surgery, radiation therapy, participation
             in other investigational trials and have recovered from clinically significant
             toxicities of these prior treatments

          -  Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit, OR

               -  Are surgically sterile, OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception, at the same time, from the time of signing the informed consent
                  form through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.)

          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree
             to one of the following:

               -  Agree to practice effective barrier contraception during the entire study
                  treatment period and through 90 days after the last dose of study drug, OR

               -  Agree to practice true abstinence when this is in line with the preferred and
                  usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation,
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
                  of contraception.).

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Patients who are Ph+ ALL who are naive to therapy with an approved tyrosine kinase
             inhibitor.

          -  Prior exposure to ≥350 mg/m2 of anthracycline (in doxorubicin equivalent dosing), or
             left ventricular fractional shortening less than 50%.

          -  Failure to have fully recovered (ie, ≤ Grade 2 toxicity) from the effects of prior
             chemotherapy regardless of the interval since last treatment.

          -  Major surgery within 14 days before enrollment.

          -  Chemotherapy in the last 14 days. (Steroids or Intrathecal chemotherapy will be
             allowed).

          -  Systemic treatment, within 7 days before study enrollment, with strong inhibitors of
             cytochrome P450 1A2 (CYP1A2) (e.g., fluvoxamine, enoxacin, ciprofloxacin), strong
             inhibitors of cytochrome P4503A (CYP3A) (e.g., clarithromycin, telithromycin,
             itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A
             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital),
             or use of Ginkgo biloba or St. John's wort.

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, or psychiatric illness/social
             situations that would limit compliance with study requirements. Patients receiving
             intravenous antibiotics for infections that are under control may be included in this
             study.

          -  Known allergy to any of the study medications, their analogues, or excipients in the
             various formulations of any agent.

          -  Inability to swallow oral medication, inability or unwillingness to comply with the
             drug administration requirements, or GI procedure that could interfere with the oral
             absorption or tolerance of treatment.

          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are
             not excluded if they have undergone complete resection.

          -  Patient has ≥ Grade 2 peripheral neuropathy.

          -  Participation in clinical trials with other investigational agents not included in
             this trial, within 14 days of the start of this trial and throughout the duration of
             this trial.

          -  Female patients who are breastfeeding or have a positive serum pregnancy test during
             the screening period or a positive urine pregnancy test on Day 1 before first dose of
             study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab L Atallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 5, 2013</study_first_submitted>
  <study_first_submitted_qc>June 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <results_first_submitted>August 13, 2019</results_first_submitted>
  <results_first_submitted_qc>December 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Ehab L Atallah</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01887587/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01887587/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>(Modified VXLD) Plus MLN9708</title>
          <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
Dexamethasone- 10 mg/m2 orally or IV on days 1-14
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
For patients without central nervous system (CNS) involvement:
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)
For patients with CNS involvement:
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>(Modified VXLD) Plus MLN9708</title>
          <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
Dexamethasone- 10 mg/m2 orally or IV on days 1-14
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
For patients without CNS involvement:
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)
For patients with CNS involvement:
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).
MLN9708
Vincristine
Doxorubicin
Dexamethasone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="25" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events.</title>
        <description>Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment.</description>
        <time_frame>Baseline to 30 days post treatment; approximately 8 weeks</time_frame>
        <population>At dose level one, 3 patients who were enrolled. The protocol was amended to remove PEGaspargase from the regimen. Two additional patients were enrolled on dose level one.</population>
        <group_list>
          <group group_id="O1">
            <title>(Modified VXLD) Plus MLN9708</title>
            <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
Dexamethasone- 10 mg/m2 orally or IV on days 1-14
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
For patients without CNS involvement:
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)
For patients with CNS involvement:
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).
MLN9708
Vincristine
Doxorubicin
Dexamethasone</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events.</title>
          <description>Safety, tolerability will be assessed by counting the number of participants experiencing adverse events at 8 weeks post treatment.</description>
          <population>At dose level one, 3 patients who were enrolled. The protocol was amended to remove PEGaspargase from the regimen. Two additional patients were enrolled on dose level one.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Optimal Dose of MLN9708</title>
        <description>This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.</description>
        <time_frame>8 Weeks</time_frame>
        <population>All five subjects received the same 2.3 mg oral dose of MLN9708.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified VXLD Plus MLN9708</title>
            <description>Vincristine -1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
Dexamethasone - 10 mg/m2 orally or IV on days 1-14
Doxorubicin - 60 mg/m2 on day 1 by IV bolus.
MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Subsequent escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.
For patients without CNS involvement:
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)
For patients with CNS involvement:
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day).</description>
          </group>
        </group_list>
        <measure>
          <title>Optimal Dose of MLN9708</title>
          <description>This measure will be the maximum tolerated dose (MTD) at which no more than 1 Dose Limiting Toxicity (DLT) is observed. The starting dose of MLN9708 will be 2.3 mg orally on days 1, 8 and 15. If no DLT is seen in the first 3 patients, the dose will be increased to 3 mg and then to 4 mg orally on days 1, 8 and 15 in a classic 3 +3 phase I design. We will not attempt to increase the dose beyond 4 mg orally which, if achieved with acceptable toxicity, would be accepted as the recommended phase 2 dose (RP2D). 0 of 3 DLTs would allow escalation to the next dose level. 1 of 3 DLTs will require expanding to six patients; 1 of 6 DLTs will allow escalation again. 2 DLTs will require dose de-escalation.</description>
          <population>All five subjects received the same 2.3 mg oral dose of MLN9708.</population>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks following last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>(Modified VXLD) Plus MLN9708</title>
          <description>Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22
Dexamethasone- 10 mg/m2 orally or IV on days 1-14
Doxorubicin- 60 mg/m2 on day 1 by IV bolus.
For patients without CNS involvement:
Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)
Methotrexate 12 mg will be administered intrathecally on day 8 (+/-1 day)
For patients with CNS involvement:
-Cytarabine 100 mg will be administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day)).
MLN9708
Vincristine
Doxorubicin
Dexamethasone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Increased blood bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ehab Atallah, MD</name_or_title>
      <organization>Medical College of Wisconsin</organization>
      <phone>414-805-8900</phone>
      <email>eatallah@mcw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

